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Transient Receptor Potential Vanilloid-1 Signaling as
a Regulator of Human Sebocyte Biology
Bala´zs I. To´th1,2, Tama´s Ge´czy1, Zolta´n Griger1, Aniko´ Do´zsa3, Holger Seltmann4,5,6, La´szlo´ Kova´cs1,2,
La´szlo´ Nagy3, Christos C. Zouboulis4,5,6,7, Ralf Paus8 and Tama´s Bı´ro´1,2
Transient receptor potential vanilloid-1 (TRPV1), originally described as a central integrator of nociception, is
expressed on human epidermal and hair follicle keratinocytes and is involved in regulation of cell growth and
death. In human pilosebaceous units, we had shown that TRPV1 stimulation inhibits hair shaft elongation and
matrix keratinocyte proliferation, and induces premature hair follicle regression and keratinocyte apoptosis. In
the current study, we have explored the role of TRPV1-mediated signaling in sebaceous gland (SG) biology,
using a human sebocyte cell culture model (SZ95 sebocytes). Demonstrating that human skin SG in situ and
SZ95 sebocytes in vitro express TRPV1, we show that the prototypic TRPV1 agonist, capsaicin, selectively inhibits
basal and arachidonic acid-induced lipid synthesis in a dose-, time-, and extracellular calcium-dependent and a
TRPV1-specific manner. Low-dose capsaicin stimulates cellular proliferation via TRPV1, whereas higher
concentrations inhibit sebocyte growth and induce cell death independent of TRPV1. Moreover, capsaicin
suppresses the expression of genes involved in lipid homeostasis and of selected proinflammatory cytokines.
Collectively, these findings support the concept that TRPV1 signaling is a significant, previously unreported
player in human sebocyte biology and identify TRPV1 as a promising target in the clinical management of
inflammatory SG disorders (for example, acne vulgaris).
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INTRODUCTION
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is the pun-
gent ingredient of hot chili peppers (Jancso´, 1960; Szolcsa´nyi,
1977). When applied topically to the skin, it initiates a
classical ‘‘multiple response’’ of pain, desensitization, neuro-
genic inflammation, and neurotoxicity (reviewed in Holzer,
1991; Sza´lla´si and Blumberg, 1999). These actions of
capsaicin establish the basis for its therapeutic application;
indeed, capsaicin is widely used in the therapy of several
dermatoses, such as neuropathies, psoriasis, pruritus, and
prurigo nodularis (reviewed in Biro´ et al., 2005; Paus et al.,
2006, Steinhoff et al., 2006).
The above effects previously were exclusively attributed to
the action of capsaicin on nociceptive sensory neurons
expressing transient receptor potential vanilloid-1 (TRPV1),
the molecular target of capsaicin (Caterina et al., 1997;
Tominaga et al., 1998). The activation of this nonselective,
calcium (Ca)-permeable channel on the nociceptors first
results in action potential firing and initiation of pain
sensation (Bevan et al., 1993). In addition, TRPV1-mediated
signaling also induces neuropeptide release (Szolcsa´nyi,
1977; Holzer, 1991; Sza´lla´si and Blumberg, 1999) which,
in turn, initiates vasodilation, flare, and edema (characteristic
signs of neurogenic inflammation; Geppetti and Holzer,
1996). Finally, prolonged application of capsaicin evokes
desensitization and/or degeneration of sensory afferents
leading to cessation of pain sensation (reviewed in Holzer,
1991; Sza´lla´si and Blumberg, 1999).
Recent reports, however, have unambiguously identified
the presence of TRPV1 on numerous non-neuronal cell types
as well. We and others have found that functional TRPV1 is
expressed, for example, on mast cells, dendritic cells, and
both epidermal and hair follicle keratinocytes in situ (Bı´ro´
et al., 1998; Birder et al., 2001; Ost et al., 2002; Lazzeri
et al., 2004; Sta¨nder et al., 2004; Bodo´ et al., 2004, 2005; Li
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et al., 2007). Studying organ-cultured human hair follicles
and cultured epidermal HaCaT keratinocytes, we have shown
that TRPV1 activation by capsaicin results in a TRPV1-
specific inhibition of hair growth and proliferation, and
induction of apoptosis and catagen (Bodo´ et al., 2005). These
findings make it mandatory to carefully consider the multiple
direct, growth-modulatory actions of capsaicin on non-
neuronal cell populations in human skin (Biro´ et al., 2005;
Paus et al., 2006; Steinhoff et al., 2006).
Given the instructiveness of pilosebaceous units for explor-
ing nonclassical functions of TRPV1-mediated signaling in
human skin biology (Bodo´ et al., 2005), it is interesting to note
that TRPV1 immunoreactivity is also found in the human
sebaceous gland (SG; Bodo´ et al., 2004). Moreover, reportedly
differentiated (mature) sebocytes show a higher level of TRPV1
immunoreactivity in situ than less differentiated ones (Sta¨nder
et al., 2004), suggesting a potential role of TRPV1 in the control
of sebocyte proliferation and/or differentiation. However, the
biological effects of TRPV1 agonists on the proliferation,
differentiation, and apoptosis of sebocytes (which differentiate
from outer root sheath hair follicle keratinocytes (Thody and
Shuster, 1989; Wro´bel et al., 2003)) remain to be dissected.
Sebocytes, engage in holocrine (sebum) secretion, are major
site of hormone synthesis and metabolism in human skin
(Zouboulis et al., 2005; Alestas et al., 2006; Zhang et al., 2006),
and express numerous receptor-coupled pathways that were
originally described chiefly on neurons (Zouboulis et al., 2002;
Zouboulis and Bohm, 2004).
Human sebocytes, therefore, provide a highly instructive
research tool for exploring nonclassical TRPV1 functions,
which promises additional sets of information that perfectly
complement those obtainable with human hair follicle. In the
current study, we have therefore investigated the effects of
capsaicin on SZ95 sebocytes—a human SG-derived immor-
talized cell line that possesses striking functional similarities
to those of primary human sebocytes (Zouboulis et al.,
1999)—and have dissected the corresponding role of TRPV1
signaling.
RESULTS
TRPV1 is expressed on human SG in situ and on human SZ95
sebocytes
Using immunohistochemistry, confirming our previous
findings (Bodo´ et al., 2004), we first have shown that human
SG epithelial cells indeed express TRPV1 in situ (Figure 1a
and b). Moreover, we also found (similar to earlier reports;
Sta¨nder et al., 2004) that TRPV1-specific immunosignals
were more prominent on the more differentiated (matured)
SG cells (Figure 1b).
We then measured the existence of TRPV1 on SZ95
sebocytes. Using various immunocytochemical methods,
western blotting, and quantitative ‘‘real-time’’ PCR (Q-PCR),
we here provide evidence that SZ95 cells also express TRPV1
on the gene and protein level (Figure 1c–f). Interestingly,
similar to cultured normal human epidermal and human
immortalized HaCaT keratinocytes (Denda et al., 2001; Bodo´
et al., 2004, 2005), the TRPV1-specific immunoreactivity was
inhomogeneous in the cell culture (Figure 1c and d), possibly
because the proliferation and differentiation status of the cells
affect the actual expression level of TRPV1. This hypothesis
was supported by the observation that the level of TRPV1-
specific mRNA transcripts and of TRPV1 protein markedly
increased in parallel with the culturing time, with TRPV1
being highest in the more ‘‘older’’ (hence possibly more
differentiated) cultures (Figure 1e and f).
Capsaicin selectively inhibits basal and arachidonic acid-
induced lipid synthesis of SZ95 sebocytes
One of the main hallmarks of sebocyte differentiation is the
synthesis of various lipids, among which neutral lipids form a
major part (Rosenfield, 1989; Thody and Shuster, 1989;
Doran et al., 1991, Zouboulis et al., 1998). Therefore, we
investigated the effect of capsaicin on the lipid content of
cultured SZ95 sebocytes. Nile red staining-based quantitative
fluorometric imaging plate reader (FLIPR) measurement
revealed that capsaicin treatment (up to 48 hours) signifi-
cantly inhibited basal synthesis of both neutral and polar
lipids in a dose-dependent fashion (Figure 2a). Importantly,
flow cytometry analysis showed that this effect of capsaicin
was not accompanied by changes in sebocyte size or
granulation (Figure 3a) the increase of which comprises
further characteristics of sebocyte differentiation (Rosenfield
1989; Thody and Shuster, 1989; Zouboulis et al., 1998; Sato
et al., 2001). Moreover, capsaicin did not induce cell death of
any form (apoptosis, necrosis); namely, application of
capsaicin did not significantly alter the viable cell number
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT)-based colorimetric proliferation assay) and, did
not induce necrotic (glucose-6-phophate-dehydrogenase
(G6PD) release assay) or apoptotic cell death (fluorimetric
measurement of the mitochondrial membrane potential, flow
cytometry analysis of the number of Annexin-V/propidium
iodide-positive cells; Figures 2b–d, 3b).
These data suggest that TPRV1 stimulation by capsaicin
selectively modulates sebocyte lipid synthesis. As we have
previously shown (Wro´bel et al., 2003; Alestas et al., 2006),
one of the most effective inducers of lipid synthesis in SZ95
sebocytes is arachidonic acid (AA). Therefore, we were also
interested in whether or not capsaicin also affects AA-
induced lipid formation. Capsaicin markedly and dose
dependently counteracted the well-recognized effect of
50 mM AA to dramatically induce (chiefly neutral) lipid
accumulation in SZ95 sebocytes (Figure 4a and b).
Our previous studies have also shown that the effect of AA
to promote lipid synthesis in SZ95 sebocytes was accom-
panied by the induction of sebocyte apoptosis (Wro´bel et al.,
2003). Therefore, we also investigated the action of capsaicin
on the AA-induced apoptotic process. As expected, AA
elevated the number of apoptotic cells (Annexin-V/propidium
iodide) and suppressed the mitochondrial membrane poten-
tial (Figures 3b and 4c). In contrast to its effect on AA-
stimulated lipid accumulation, capsaicin was unable to
prevent the apoptosis-inducing action of AA (Figure 4c). This
suggests that TRPV1 stimulation specifically targeted sebo-
cyte lipid synthesis (Figure 4b) (note that AA did not cause
necrotic cell death, Figure 4d).
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The effect of capsaicin to inhibit lipid synthesis is mediated by
TRPV1
On most TRPV1-expressing cell types, this receptor
functions as a Ca-permeable channel (Bevan et al., 1993;
Caterina et al., 1997; Bı´ro´ et al., 1998; Birder et al., 2001;
Inoue et al., 2002; Bodo´ et al., 2005). Therefore, we next
investigated the role of Ca in the TRPV1-mediated effects
on SZ95 sebocytes. As seen in Figure 5a and b, the activity
of the TRPV1 agonist to suppress basal and highly elevated,
AA-induced lipid accumulation was almost completely
abrogated by lowering the extracellular Ca concentration
([Ca2þ ]e) of the culturing medium (to 0.25 mM), Although
changes in [Ca2þ ]e may affect multiple cell signaling
pathways, these findings proposed that the actions
of capsaicin are mediated by TRPV1-specific [Ca2þ ]i
elevations.
To further investigate the issue of specificity, we then
measured the effect of a specific TRPV1 antagonist, iodo-
resiniferatoxin (I-RTX; Wahl et al., 2001). This TRPV1
antagonist abrogated the effect of capsaicin to inhibit basal
and AA-induced lipid accumulation in SZ95 cells (Figure 5c).
The TRPV1 specificity of the effect of capsaicin was further
assessed by RNA interference (RNAi). Western blot and
Q-PCR analysis revealed that the expression of TRPV1 was
significantly ‘‘knocked-down’’ by both RNAi probes at day 2
after transfection (Figure 5d and e) and remained suppressed
also on day 3 (data not shown). Scrambled RNAi probes
possessed no effects on the expression of TRPV1, indicating
the specificity of the procedure. Similar to the actions of
I-RTX, RNAi-mediated knockdown of TRPV1 resulted in the
loss of effect of capsaicin to inhibit basal and AA-evoked lipid
synthesis (Figure 5f ).
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Figure 1. TRPV1 is expressed on human sebaceous gland in situ and on cultured human SZ95 sebocytes. (a, b) TRPV1-specific immunoreactivity (ir), as
revealed by a streptavidine-biotin-complex technique, on human sebaceous gland (SG) epithelial cells in situ. Note that the membrane-localized TRPV1-ir is
stronger on the central differentiated (d.s.) than on peripheral undifferentiated (ud.s.) sebaceous cells. As an ‘‘internal positive control’’, TRPV1-ir on a cutaneous
nerve fiber is shown. NC, preabsorption negative control. (c, d) TRPV1-ir as determined by immunofluorescence (Texas red, c) or light microscopy
(diaminobenzydine, d) labeling in SZ95 sebocytes. Nuclei were counterstained by DAPI (blue fluorescence, c) or hematoxylin (d). NC, preabsorption negative
control. Scale bars¼200 mM (a), 100 mM (b), 60 mM (c), 30 mM (d). (e) Western blot analysis. TRPV1 expression was determined on cell lysates of SZ95 sebocytes
harvested at various confluences. For positive controls, CHO cells overexpressing human TRPV1 were employed. Equal loading was assessed by determining
expression of cytochrome C (Cyt-C). In each sample, the amount of TRPV1 was quantitated by densitometry and normalized to those of Cyt-C (normalized
optical density, OD, values are indicated); OD value of the ‘‘50% confluence’’ sample was defined as 100%. (f) Q-PCR analysis of TRPV1 expression on cell
lysates of SZ95 sebocytes harvested at various confluences. Data of TRPV1 expression were normalized to the level of GAPDH of the same sample and are
expressed as mean±SEM of three independent determinations. Three additional experiments yielded similar results.
www.jidonline.org 331
BI To´th et al.
TRPV1 Controls Sebocyte Biology
CCCP10,0001,0001001010.10
CAPS (nM)
120
100
80
60
40
20
M
ito
ch
on
dr
ia
l m
em
br
an
e 
po
te
nt
ia
l
(m
ea
n o
f c
on
tro
l =
 10
0%
)
lysis10,0001,0001001010.10
CAPS (nM)
10
20
30
90
100
110
120
G
6P
D 
re
le
as
e
(m
ea
n o
f ly
se
d c
ell
s =
 10
0%
)
10,0001,0001001010.10
CAPS (nM)
20
40
60
80
100
120
Vi
ab
ilit
y
(m
ea
n o
f c
on
tro
l =
 10
0%
)
10,0001,0001001010.10
CAPS (nM)
20
40
60
80
100
120
Li
pi
ds
(m
ea
n o
f c
on
tro
l =
 10
0%
)
*
*
**
*
Neutral lipids
Polar lipids
Figure 2. Capsaicin inhibits basal lipid synthesis of SZ95 sebocytes without affecting cell viability. Cells (20,000 cells per well) were cultured in 96-well black-
well/clear-bottom plates in quadruplicates and were treated with various concentrations of capsaicin (CAPS) for 24 hours. (a) Quantitative measurement of
intracellular lipids as assessed by Nile red labeling followed by FLIPR measurement. (b) Determination of viable cell number by colorimetric MTT assay. (c)
Quantitative measurement of necrotic cell death by FLIPR-based G6PD release assay. (d) Quantitative measurement of apoptotic cell death by FLIPR-based
DilC1(5) assay reflecting mitochondrial membrane potential. Data (mean±SEM) are expressed as a percentage of the mean value (defined as 100%) of the
vehicle-treated control group (a, b, d) or of maximal G6PD release (induced by Triton X-100, lysis) (c). For positive control, that is, to induce apoptosis (and
decrease mitochondrial membrane potential), 50mM m-chlorophenylhydrazone (CCCP) was employed (d). *Significant (Po0.05) differences compared to the
vehicle-treated control groups. Three additional experiments yielded similar results.
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Figure 3. Unlike arachidonic acid, capsaicin does not affect size and granulation of SZ95 sebocytes, and does not induce apoptosis. (a) Phenotypic
characterization of SZ95 sebocytes. Cells were treated by 10mM capsaicin or 10mM arachidonic acid (or vehicle, control) for 24 hours. Flow cytometry analysis
was then performed to determine forward scatter (size) and side scatter (granulation) values. (b) Measurement of apoptosis. Following the above treatment, cells
were harvested, stained with an Annexin-V-FITC and propidium iodide kit, and fluorescence intensity values were detected by flow cytometry. Three additional
experiments yielded similar results.
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Intriguingly, we also found that I-RTX (Figure 5c) as well as
RNAi-mediated silencing of TRPV1 (Figure 5f) moderately
(yet significantly) augmented the stimulatory effect of AA on
lipid synthesis. Collectively, these findings suggest that the
action of capsaicin was specifically mediated by TRPV1 and,
furthermore, that TRPV1 may also act as an endogenous
receptor channel to inhibit lipid formation of SZ95 sebocytes.
Prolonged application of capsaicin induces a biphasic alteration
in cellular proliferation of SZ95 sebocytes, partly via the
activation of TRPV1
Previously, we had found that capsaicin, when applied for
3–5 days, markedly inhibits the proliferation of human
keratinocytes in a TRPV1-dependent fashion (Bodo´ et al.,
2005). Therefore, we also investigated the effect of long-term
capsaicin application on the proliferation of SZ95 sebocytes.
For this experiment, the serum content of the culture medium
was decreased to 3% so as to be able to investigate both
possible growth-promoting and -inhibitory actions (under
these culture conditions, the SZ95 sebocytes fully survived
but exhibited only an insignificant growth rate, Figure 6a).
Up to day 3, capsaicin (applied at concentrations as high
as 30 mM) did not significantly alter the growth of SZ95 cells
(Figure 6a). However, from day 3, higher doses (1–30 mM) of
capsaicin significantly reduced the number of viable cells
(Figure 6b), most probably due to the induction of necrotic
cell death (SYTOX green assay; Figure 6c). However, of great
importance, low doses (0.01–100 nM) of capsaicin signifi-
cantly increased the viable cell number, presumably due to
the stimulation of proliferation (Figure 6a and b).
We also tested whether the above, biphasic action of
capsaicin on cell growth was mediated by TRPV1. First, we
repeated the above experiments in low-Ca (0.25 mM)
medium. As seen in Figure 6d, suppression of the [Ca2þ ]e
fully abrogated the growth-promoting effect of low capsaicin
doses. In contrast, this intervention did not modify the
growth-inhibitory and cytotoxic effect of (high concentrations
of) the vanilloid. In good accord with these findings, the
TRPV1 antagonist I-RTX completely prevented the growth-
promoting action of low capsaicin concentrations (Figure 6d).
However, the TRPV1 antagonist was unable to modify the
effect of high capsaicin doses. These findings suggest that the
growth-promoting effect of low capsaicin doses was indeed
mediated by TRPV1, whereas the growth-inhibitory action of
the high-dose vanilloid appeared to be receptor independent.
Capsaicin differentially alters expressions of genes involved in
the regulation of lipid synthesis and of proinflammatory
cytokines
Capsaicin treatment of human skin keratinocytes significantly
alters the gene expression profile and the cytokine production
of treated cells (Bı´ro´ et al., 1998; Southall et al., 2003; Bodo´
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Figure 4. Capsaicin inhibits arachidonic acid-induced lipid synthesis, but not apoptosis, of SZ95 sebocytes. (a) Semiquantitative detection of sebaceous lipids.
Cells were treated with 50 mM arachidonic acid (AA) or with 50 mM AAþ 10mM capsaicin (CAPS) for 24 hours and lipids were labeled by Oil red O solution
(nuclei were counterstained with hematoxylin). Scale bars¼ 10mM. (b–d) Cells (20,000 cells per well) were cultured in 96-well black-well/clear-bottom plates in
quadruplicates and were treated with combinations of various concentrations of CAPS and 50mM AA for 24 hours. (b) Quantitative measurement of intracellular
lipids as assessed by Nile red labeling followed by FLIPR measurement. (c) Quantitative measurement of apoptotic cell death by FLIPR-based DilC1(5) assay. (d)
Quantitative measurement of necrotic cell death by FLIPR-based G6PD release assay. Data (mean±SEM) are expressed as a percentage of the mean value
(defined as 100%) of the vehicle-treated control group (b, c) or of maximal G6PD release (induced by Triton X-100, lysis) (c). *Significant (Po0.05) differences
compared to the vehicle-treated control groups (b, c) whereas # marks the significant (Po0.05) differences compared to the 50mM AA-treated control group (ie
without CAPS, b). Three additional experiments yielded similar results.
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et al., 2005). Therefore, we also investigated this phenom-
enon in SZ95 cells, concentrating on selected genes
recognized to be involved in the stimulation of lipid synthesis
in SZ95 sebocytes (Rosenfield et al., 1999; Chen et al., 2003;
Trivedi et al., 2006; see detailed description in Table 1 and in
‘‘Discussion’’). This was complemented by analyses of
selected proinflammatory cytokines that had previously been
found to be expressed by these cells (Alestas et al., 2006).
As assessed by Q-PCR, the capsaicin-induced transcrip-
tional modulation of lipid synthesis-related genes involved
was markedly time dependent (Table 1). However, after
24 hours treatment (that is, the time-point at which lipid
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group regarded as 100%. (e) Expression of TRPV1 after RNAi was also assessed by Q-PCR (panel represents data at day 2). Values of TRPV1 expression were
normalized to the level of GAPDH of the same sample and are expressed as mean±SEM of three independent determinations. *Significant (Po0.05) differences
compared to the C group. (f) At day 2 after transfection, cells were treated with the indicated combinations of 10mM CAPS and 50mM AA for 24 hours.
Intracellular lipids were then quantitatively measured by Nile red labeling followed by FLIPR measurement. Data (mean±SEM) are expressed as a percentage of
the mean value (defined as 100%) of the C group. *Significant (Po0.05) differences Two additional experiments yielded similar results.
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synthesis was strongly suppressed, see above), capsaicin
significantly reduced the expression of all genes that are
recognized as stimulators of lipid synthesis. Interestingly,
among the three proinflammatory cytokines investigated,
vanilloid treatment selectively and markedly decreased the
level of IL-1b (more than 70%) without affecting that of IL-6
and tumor necrosis factor-a (Table 1). These findings suggest
that TRPV1-mediated-signaling pathway(s) modulate sebo-
cyte biology also by regulating key genes of lipid synthesis
and by impacting on the cytokine network of human SZ95
sebocytes.
DISCUSSION
The functional data reported here introduce TRPV1 as a
significant new player in human sebocyte biology, with
TRPV1-mediated signaling exerting profound, dose-dependent
effects on sebocyte lipid synthesis, proliferation, cell death,
gene expression, and cytokine production. Along with
previous findings of our laboratories on human keratinocytes
(Bodo´ et al., 2005), this underscores the concept that TRPV1
signaling targets previously unappreciated, nonclassical
mechanisms in human skin. This, in turn, suggests that the
physiological functions of TRPV1 and its elusive endogenous
ligands in human skin far extend beyond that of sensory
neuron-coupled nociception.
Most of the actions of capsaicin studied here appeared to
be mediated by TRPV1-coupled signaling. This is supported
by (1) TRPV1 expression on the gene and protein level in
human SZ95 sebocytes (Figure 1); (2) the inhibitory action of
capsaicin on basal and AA-induced lipid synthesis (Figures
2a, 4a, b, 5a and b); (3) the effect of the TRPV1-antagonist
I-RTX (Figures 5c and 6d) and the RNAi-mediated silencing of
TRPV1 (Figure 5d–f). That the effects of capsaicin to inhibit
lipid formation and promote cell growth were also inhibited
by reducing [Ca2þ ]e (Figures 5b and 6d) further suggests that
these actions were executed by a TRPV1-mediated Ca
influx—similar to what has been described for various
neuronal and non-neuronal cell populations, including
human keratinocytes (Bevan et al., 1993; Caterina et al.,
1997; Bı´ro´ et al., 1998; Birder et al., 2001; Inoue et al., 2002;
Bodo´ et al., 2005).
In addition, we also observed that capsaicin, when
administered for longer durations at high concentrations,
significantly inhibited proliferation and induced cell
death (Figure 6), again similar to effects seen on epidermal
HaCaT and hair follicle-derived keratinocytes (Bodo´ et al.,
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Figure 6. Prolonged application of capsaicin exerts a biphasic effect on
cellular proliferation and viability of SZ95 sebocytes. (a) Cells (40,000 cells
per well) were cultured in low serum (3%) medium in quadruplicates, treated
with various concentrations of capsaicin (CAPS) for the time indicated, and
the viable cell number was determined by colorimetric MTT assay. (b)
Concentration dependence of the effect of CAPS on the viable cell number at
day 6 (MTT assay). (c) Concentration dependence of the effect of CAPS on
necrotic cell death at day 6 as assessed by quantitative FLIPR-based SYTOX
green assay. (d) Cells were treated with various concentrations of CAPS in
high-Ca (2 mM) and low-Ca (0.25 mM) media as well as combinations of
various concentrations of CAPS and 50 nM iodo-resiniferatoxin (I-RTX), and
MTT assay was performed at day 6. Data (mean±SEM) are expressed as a
percentage of the mean value (defined as 100%) of the vehicle-treated control
group. *Significant (Po0.05) differences compared to the vehicle-treated
control groups (a–d) whereas # marks the significant (Po0.05) differences
compared to the 1 nM CAPS-treated control group in high-Ca medium (d).
Three additional experiments yielded similar results.
Table 1. Effect of capsaicin treatment on gene
expression of transcription factors known as
stimulators of lipid synthesis (A) and on production of
proinflammatory cytokines (B) in SZ95 sebocytes
Capsaicin, 6 h
(% of control)
Capsaicin, 24 h
(% of control)
(A) Gene expression
PPARa 87±17 63±141
PPARg 95±11 58±161
PPARd 123±19 51±111
RXRa 103±11 54±141
RXRb 34±131 69±91
(B) Cytokine release
IL-1b NA 27±91
IL-6 NA 95±13
TNFa NA 106±21
NA, not applicable; PPAR, peroxisome proliferator-activated receptor;
RXR, retinoid X receptor; TNF, tumor necrosis factor-a.
Cells were treated with either vehicle or with 1 mM capsaicin for the times
indicated. (A) Cells were then harvested and gene expression of members
of the PPAR and RXR nuclear transcription factor families was determined
by Q-PCR. (B) In another experimental setup, supernatants were
collected, and amounts of the released IL-1b, IL-6, and TNFa were
determined using specific OptEIA kits. In both cases, values of the
capsaicin-treated samples were normalized as percentage of the control
regarded as 100 %. Data are expressed as mean±SEM of four
independent determinations.
1Marks significant (Po0.05) differences compared to the vehicle-treated
control groups.
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2005). However, these effects were not modified by the
TRPV1 antagonist I-RTX or by manipulating [Ca2þ ]e (Figure
6d) suggesting a TRPV1-independent mode of action. These
findings were in contrast to our previous results on various
keratinocytes where the growth inhibitory action of capsaicin
was mediated by TRPV1 (Bodo´ et al., 2005). It appears,
therefore, that although functional TRPV1-mediated signaling
does exist on numerous cell populations of the human skin,
its cellular ‘‘consequences’’ (especially in relation to regula-
tion of cell growth) are markedly cell-type dependent.
Members of the peroxisome proliferator-activated receptor
(PPAR) (Desvergne and Wahli, 1999; Kersten et al., 2000)
and the retinoid X receptor nuclear transcription factor
families (Keller et al., 1993, Berger and Moller, 2002) are
recognized as key regulators of lipid homeostasis (Gregoire
et al., 1998; Chawla et al., 2001; Nagy and Szanto, 2005,
Szatmari et al., 2007). With respect to sebocyte biology,
PPAR ligands stimulate lipid synthesis both in animal models
(Rosenfield et al., 1999) and on cultured human immorta-
lized SZ95 and SEB-1 sebocytes that express distinct PPARs
(Chen et al., 2003; Alestas et al., 2006; Trivedi et al., 2006).
Therefore, our observation that capsaicin treatment down-
regulated the transcription of all PPARs and retinoid X
receptors investigated here (Table 1) suggests that the
suppression of lipid synthesis upon activation of TRPV1-
and Ca-coupled signaling is mediated by decreasing the
activity of the transcription factors. Consequently, these
exciting data invite further, more extensive (most desirably
MicroArray) experiments to define changes in the global gene
expression profile in sebocytes upon vanilloid treatment (we
have successfully employed this approach to identify
previously unknown target genes of TRPV1 signaling in
cultured human hair follicles, Bodo´ et al., 2005).
Further intriguing results were obtained when we mea-
sured the effect of capsaicin on the action of AA, one of the
key stimulators of lipid synthesis and inducer of apoptosis in
sebocytes (Wro´bel et al., 2003; Alestas et al., 2006). Previous
studies have identified AA and certain of its derivatives (for
example, leukotrienes) as potent endogenous ligands of
TRPV1 (Hwang et al., 2000; Di Marzo et al., 2002).
However, as shown here by several complementary assays,
AA and capsaicin turned out to act in an opposite manner
with respect to their modulation of sebocyte lipid synthesis
(Figures 2a, 4a and b). Moreover, capsaicin treatment
markedly abrogated the AA-induced lipid formation in a
TRPV1- and [Ca2þ ]e-dependent manners (Figures 4a, b, 5).
As AA and its metabolites also operate as potent activators for
various PPARs (Devchand et al., 1996; Desvergne and Wahli,
1999), it is conceivable that the inhibitory action of TRPV1 on
the effect of AA is mediated (at least in part) by the capsaicin-
induced downregulation of most of PPAR genes stimulating
lipid formation. Furthermore, if we also take into considera-
tion that the TRPV1 antagonist I-RTX alone as well as the
RNAi-mediated silencing of TRPV1 significantly augmented
AA-stimulated lipid synthesis (Figure 5c and f), TRPV1
signaling here surfaces as a previously unreported, endogen-
ously active receptor-channel mechanism that keeps both
constitutive and induced sebocyte lipid synthesis in check.
(Evidently, the in vivo relevance of this proposal should be
extensively investigated in the near future).
Besides stimulating lipid synthesis, AA and its derivatives
also augment sebocyte production of a wide-array of proin-
flammatory cytokines (Alestas et al., 2006). Therefore, the
overall cellular modifications induced by AA strikingly
resemble those seen in acne vulgaris, a common, multi-factorial
pilosebaceous inflammatory skin disease in which lipid
synthesis of sebocytes are pathologically increased (reviewed
in Zouboulis et al., 1998; Zouboulis, 2004; Zouboulis et al.,
2005). Therefore, our previously unreported findings that
capsaicin (1) inhibits AA-induced lipid synthesis; (2) down-
regulates nuclear transcription factors that stimulate lipid
accumulation; and (3) suppresses proinflammatory cytokine
production (Table 1) raise the question whether insufficient
TRPV1-mediated signaling contributes to acne pathogenesis (for
example, by causing excess lipid production and by failing to
suppresses local proinflammatory cytokine production).
Along these lines, our study will hopefully inspire one to
systemically explore in future studies how certain vanilloids
and the related TRPV1 signaling can be manipulated in a
clinically desired manner by endogenous and/or exogenous
ligands in the management of acne (and possibly other
relevant sebaceous gland diseases). In these putative trials, on
the one hand, prolonged stimulation of neuronal TRPV1 by,
for example, topically administered capsaicin may result in
the depletion of the neuropeptide content of the sensory
afferents—among which substance P was shown to promote
lipid synthesis of sebocytes (Toyoda and Morohashi, 2001)
and was implicated in acne pathogenesis (Zouboulis,
2004)—hence indirectly suspending pathological lipid accu-
mulation. On the other hand, as described in the current
study, the additional ‘‘chronic’’ activation of TRPV1 signaling
on sebocytes may directly inhibit synthesis of lipids and pro-
inflammatory cytokines. Therefore, when applied topically,
vanilloids may ‘‘kill two birds with one stone’’ to fight acne.
MATERIALS AND METHODS
Cell culturing
Human immortalized SZ95 sebocytes (Zouboulis et al., 1999) were
cultured in Sebomed basal medium (Biochrom, Berlin, Germany)
supplemented with 10% fetal bovine serum (Invitrogen, Paisley,
UK), 1 mM CaCl2, 5 ng ml
1 human epidermal growth factor (Sigma-
Aldrich, St. Louis, MO), 50 U ml1 penicillin and 50 mg ml1
streptomycin (both from Biogal, Debrecen, Hungary). The final Ca
concentration of the medium was approximately 2 mM (high-Ca
medium). The low-Ca Sebomed medium was prepared to set the
Ca concentration to 0.25 mM.
Phenotypic characterization
Phenotypic characterization of SZ95 sebocytes was performed using
flow cytometry by determining the forward scatter (size) and side
scatter (granulation) values by a Coulter Epics XL (Beckman Coulter,
Fullerton, CA) flow cytometer (Bodo´ et al., 2005).
Determination of intracellular lipids
For semiquantitative detection of sebaceous lipids, cells were
cultured on glass coverslips and treated with various compounds
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for 24–48 hours. Cells were fixed in 4% paraformaldehyde, washed
in 60% isopropanol (both Sigma-Aldrich), and stained in freshly
prepared Oil red O solution (in 60% isopropanol; Sigma-Aldrich).
Nuclei were counterstained with Mayer’s hematoxylin (Sigma-
Aldrich) and coverslips were mounted in mounting medium (DAKO,
Glostrup, Denmark; Wro´bel et al., 2003).
For quantitative measurement of lipid content, cells (20,000 cells
per well) were cultured in 96-well black-well/clear-bottom plates
(Greiner Bio-One, Frickenhausen, Germany) in quadruplicates and
were treated with compounds for 24–48 hours. Subsequently,
supernatants were discarded and 100ml of a 1 mg ml1 Nile red
(Sigma-Aldrich) solution in phosphate-buffered saline was added to
each well. Fluorescence was measured on a Molecular Devices
FlexStation384 II FLIPR (Molecular Devices, San Francisco, CA).
Results are expressed as percentages of the relative fluorescence
units in comparison with the controls using 485 nm excitation and
565 nm emission wavelengths for neutral lipids, and 540 nm
excitation and 620 nm emission wavelengths for polar lipids (Alestas
et al., 2006).
Determination of viable cell numbers
The number of viable cells was determined by measuring the
conversion of the tetrazolium salt MTT (Sigma-Aldrich) to formazan
by mitochondrial dehydrogenases. Cells were plated in 96-well
multi-titer plates (20,000 or 40,000 cells per well density) in
quadruplicates and were cultured for 1–6 days. Cells were then
incubated with 0.5 mg ml1 MTT for 2 hours, and concentration of
formazan crystals was determined colorimetrically according to the
manufacturer’s protocol (Bodo´ et al., 2005).
Determination of apoptosis
A decrease in the mitochondrial membrane potential is one of the
earliest markers of apoptosis (Green and Reed, 1998; Susin et al.,
1998). Mitochondrial membrane potential of SZ95 sebocytes was
determined using a MitoProbe DiIC1(5) Assay Kit (Invitrogen). Cells
(20,000 cells per well) were cultured in 96-well black-well/clear-
bottom plates (Greiner Bio-One) in quadruplicates and were treated
with various compounds for the time indicated. After removal of
supernatants, cells were incubated for 30 minutes with DilC1(5)
working solution (30 ml per well) and the fluorescence of DilC1(5)
was measured at 630 nm excitation and 670 nm emission wave-
lengths using the above FLIPR.
In addition, further apoptosis events were also assessed by flow
cytometry according to our previous reports (Bodo´ et al., 2005) In
brief, following treatment with various agents cells were harvested
and stained with an Annexin-V-FITC/Propidium Iodide Apoptosis Kit
(Sigma-Aldrich) following the manufacturer’s protocol. Fluorescence
intensity was measured by a Coulter Epics XL (Beckman Coulter)
flow cytometer.
Determination of cytotoxicity (necrosis)
Necrotic cell death was determined by measuring the G6PD release
(G6PD Release Assay Kit, Invitrogen). The enzyme activity was
detected by a two-step enzymatic process that leads to the reduction
of resazurin into red-fluorescent resorufin. Cells (20,000 cells per
well) were cultured in 96-well black-well/clear-bottom plates
(Greiner Bio-One) in quadruplicates and treated with various
compounds for 24 hours. A 2 reaction medium was then prepared
according to the manufacturer’s protocol and added to the wells in
1:1 dilution. The fluorescence emission of resorufin was monitored
by the FLIPR device at 545 excitation and 590 emission wave-
lengths. Results are presented as the percentage of the maximal
G6PD release induced by detergent lysis of cells using undiluted
Triton X-100 (Sigma-Aldrich).
As the activity of the G6PD released from necrotic cells decreases
over 24 hours, the cytotoxic effect of long-term capsaicin treatment
was determined by SYTOX Green staining (Invitrogen). The dye is
able to penetrate (and then bind to the nucleic acids) only to necrotic
cells with ruptured plasma membranes, whereas healthy cells with
intact surface membranes show negligible SYTOX Green staining.
Cells were cultured in 96-well black-well/clear-bottom plates
(Greiner Bio-One) and treated with capsaicin up to 6 days.
Supernatants were then discarded and the cells were incubated
with 1mM SYTOX Green solution. Fluorescence of SYTOX Green
was measured at 490 nm excitation and 520 nm emission wave-
lengths using FLIPR.
Determination of cytokine release
Cells were treated in triplicates with capsaicin for 24 hours,
supernatants were collected, and the released amount of IL-1b,
IL-6, and tumor necrosis factor-a were determined using OptEIA kits
(BD Pharmingen, Franklin Lakes, NJ) according to the manufac-
turer’s protocol. Cytokine amount were expressed as percentage of
the vehicle-treated control samples (Bı´ro´ et al., 1998).
RNA interference
SZ95 sebocytes were seeded in six-well culture plates in medium
lacking antibiotics. At 50–70% confluence, medium was replaced by
serum-free OptiMEM (Invitrogen) and then cells were transfected
with two TRPV1-specific Stealth RNAi oligonucleotides
(ID, HSS111305 for no. ‘‘5’’, HSS111306 for no. ‘‘6’’, Invitrogen;
40 nM) using Lipofectamine 2000 transfection reagent (Invitrogen).
For controls, RNAi Negative Control Duplexes (scrambled RNAi,
Invitrogen) were employed. The efficacy of small-interfering RNA-
driven ‘‘knockdown’’ was daily evaluated by Q-PCR and western
blotting for 3 days (Griger et al., 2007).
RNA isolation, reverse transcription, quantitative real-time PCR
Quantitative real-time PCR was performed on an ABI Prism 7000
sequence detection system (Applied Biosystems, Foster City, CA)
using the 50 nuclease assay as detailed in our previous report (Bodo´
et al., 2005). Total RNA was isolated using TRIzol (Invitrogen) and
then 3mg of total RNA were reverse transcribed into cDNA by using
15 U of AMV reverse transcriptase (Promega, Madison, WI) and
0.025mg ml1 random primers (Promega). PCR amplification was
performed by using the TaqMan primers and probes (assay ID,
Hs00218912_m1 for human TRPV1) and the TaqMan universal PCR
master mix protocol (Applied Biosystems). As internal controls,
transcripts of glyceraldehyde 3-phosphate dehydrogenase were
determined (assay ID, Hs99999905_m1 for human glyceraldehyde
3-phosphate dehydrogenase).
To detect the expression of genes involved in the regulation of
lipid synthesis, individually designed TaqMan primers and probes
were used: forward primer GATGACAGCGACTTGGCAA, reverse
primer CTTCAATGGGCTTCACATTCA, and probe FAM-CAAACCT
GGGCGGTCTCCACTGAG-TAMRA for human PPARg; forward
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primer AGCATCCTCACCGGCAAAG, reverse primer CCACAATGT
CTCGATGTCGTG, and probe FAM-CAGCCACACGGCGCCCTT
TG-TAMRA for human PPARd; forward primer CATTACGGAGTC
CACGCGT, reverse primer ACCAGCTTGAGTCGAATCGTT, and
probe FAM-CAAACCTGGGCGGTCTCCACTGAG-TAMRA for human
PPARa; forward primer GGCCTACTGCAAGCACAAGTA, reverse
primer CAGGCGGAGCAAGAGCTTA, and probe FAM-CGAACC
TTCCCGGCTGCTCTG-TAMRA for human retinoid X receptor-a;
and a predesigned assay for human retinoid X receptor-b (Applied
Biosystems, assay ID:Hs00232774_m1). As internal controls, tran-
scripts of human cyclophyllin were determined (forward primer
ACGGCGAGCCCTTGG, reverse primer TTTCTGCTGTCTTTGGGA
CCT, and probe FAM-CGCGTCTCCTTTGAGCTGTTTGCA-TAMRA).
Immunohistochemistry
The study was approved by the Institutional Research Ethics
Committee and adhered to Declaration of Helsinki guidelines.
Normal skin samples (n¼ 5; trunk, back), obtained during plastic
surgery, were used as formaldehyde-fixed sections embedded in
paraffin (3–5 mm thickness; Bodo´ et al., 2004). To detect TRPV1, a
streptavidine-biotin-complex three-step immunohistochemical tech-
nique (DAKO) was employed. Sections were first incubated with an
anti-TRPV1 goat primary antibody against the N terminus of TRPV1
(1:50 dilution, Santa Cruz, Santa Cruz, CA), then with a biotin-
coupled anti-goat secondary antibody (1:500, DAKO), and, finally,
with streptavidine conjugated with horseradish peroxidase (1:400,
DAKO). To reveal the peroxidase activity, DAB (Vector Laboratories,
Burlingame, CA) was employed as a chromogene. Tissue samples
were finally slightly counterstained with hematoxylin (Sigma-
Aldrich) and mounted in aqueous mounting medium (DAKO).
In control experiments, specificity of TRPV1 staining was
assessed by (1) omitting the primary antibody or by incubating the
sections with the TRPV1 antibody preabsorbed with a synthetic
blocking peptide (Santa Cruz; Figure 1a); (2) using another antibody
against the C terminus of TRPV1 (Santa Cruz) that resulted in an
identical staining pattern (data not shown); and (3) performing
TRPV1 immunostaining on frozen skin sections from wild-type
C57BL/6J and TRPV1 knockout B6.129S4-Trpv1 mice (The Jackson
Laboratory, Bar Harbor, MA, data not shown; Bı´ro´ et al., 2006). For
positive controls, immunostaining on sections of rat spinal cord (data
not shown; Bodo´ et al., 2004) and on cutaneous nerves (‘‘internal
positive control’’) was employed (Figure 1b).
Immunocytochemistry
SZ95 sebocytes, seeded and cultured on sterile coverslips in 24-well
plates, were fixed in acetone, permeabilized by 0.1% Triton X-100
(Sigma-Aldrich), and then incubated with the anti-TRPV1 primary
antibody (dilution 1:50). For fluorescence staining, slides were then
incubated with Texas red-conjugated secondary antibodies (dilution
1:200, Vector Laboratories) and the nuclei were visualized using
46-diamidino-2-phenyl indole (Vector Laboratories). For light
microscopy, after staining with the primary antibody, slides
were incubated by an EnVision horseradish peroxidase-polymer-
conjugated secondary antibody (DAKO) and developed by
diaminobenzydine (DAKO). Nuclei were visualized using
hematoxylin (Sigma-Aldrich) and mounted in aqueous mounting
medium (DAKO). As negative controls, the appropriate TRPV1
antibody was either omitted from the procedure or was preincubated
with a synthetic blocking peptide (Santa Cruz; Figure 1c and d; Bodo´
et al., 2005).
Western blotting
To determine the expression of TRPV1 in SZ95 cells, the western blot
technique was applied (Bı´ro´ et al., 1998; Bodo´ et al., 2004, 2005).
Cell lysates were subjected to SDS–PAGE (8% gels were loaded with
60mg protein per lane), transferred to BioBond nitrocellulose
membranes (Whatman, Maidstone, UK), and then probed with the
above anti-TRPV1 antibody (1:100). A horseradish peroxidase-
conjugated rabbit anti-goat IgG antibody (1:1,000, Bio-Rad, Hercules
CA) was used as a secondary antibody, and the immunoreactive
bands were visualized by a SuperSignal West Pico Chemiluminescent
Substrate enhanced chemiluminescence kit (Pierce, Rockford, IL)
using LAS-3000 Intelligent Dark Box (Fuji, Tokyo, Japan). To assess
equal loading, membranes were reprobed with an anti-cytochrome C
antibody (1:50, Santa Cruz) and visualized as described above.
Statistical analysis
When applicable, data were analyzed using a two-tailed unpaired
t-test and Po0.05 values were regarded as significant differences.
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